target antigens for t-cell engager therapies in all and aml
Published 6 years ago • 126 plays • Length 1:10Download video MP4
Download video MP3
Similar videos
-
2:15
challenges with immunotherapy in aml: target antigen selection, t-cell exhaustion and more
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
5:40
current concepts and future developments in t-cell-based immunotherapy of aml
-
1:48
the challenges of choosing the right target antigen in aml compared to all
-
2:26
insights into the future of aml therapy: the increasing use of targeted agents
-
7:02
bcl11a as therapeutic target in scd: gene therapy trial
-
4:48
understanding acute myeloid leukemia - part 1
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:43
t-cell engaging treatment in aml
-
4:16
updates from amg 330 in aml
-
1:24
t-cell engaging antibodies: what lessons have we learnt?
-
11:19
immunotherapy for aml & all
-
1:11
exciting updates in all and the value of novel immunotherapies
-
2:33
novel immunotherapies in aml and insights into the future of the treatment landscape
-
3:47
the role of immunotherapy in the aml treatment landscape
-
2:41
cell avidity as a predictor of t-cell efficacy
-
1:36
targeted therapy for aml
-
8:57
outcomes of sct in t-all and t-lbl
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
4:31
limitations of targeted therapy for aml
-
1:19
new treatments for aml
-
2:36
the current treatment landscape for aml